Medtronic

# MiniMed™ 780G system

The only system with **meal detection technology*** that provides automatic adjustments and corrections† to glucose levels **every 5 minutes**§

- Provides missed bolus forgiveness[1]
- Helps to cover underestimated carb counts


Smart devices sold separately.º

*Taking a bolus 15–20 minutes before a meal helps to keep blood sugar levels under control after eating.

**Fingersticks required in manual mode and to enter SmartGuard.™ If symptoms don't match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend average of > 93% in SmartGuard.™

§ Refers to SmartGuard™ feature. Individual results may vary.

† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

1. Matejko B. et al, Diabetes Care. 2022;https://doi.org/10.2337/dc220470.

º For a list of compatible devices, visit bit.ly/CheckDevices.



# Managing blood glucose levels can be difficult

**Despite the substantial increase of CGM use,** mean A1C is not yet meeting ADA guidelines.[2]

## Each day and night, insulin needs vary

**42** factors may affect blood glucose levels[3]




### The challenge of carb counting

**50%** of patients consider counting carbs the most burdensome aspect of managing diabetes.[4]

**63%** of people with type 1 diabetes underestimated carbohydrates when tested on carb-counting accuracy.[5]

### Forgetting or neglecting to administer a bolus

**53%** Forgot to take injections[6]

**33%** skipped injections intentionally[6]

## On average, people with type 1 diabetes miss two meal doses/week.[7]

-2 = ↑ 0.4% A1C per week

Missing two doses per week can lead to an increase in A1C of up to 0.4%[7]

2. Foster NC, et al. Diabetes TechnolTher 2019; 21(2):66-72.
3. Meade LT et al.. Clin Diabetes. 2016;34(3):142-147.
4. Brazeau AS, et al. Diabetes Res Clin Pract. 2013;99:19-23.
5. Sarah C.Westen, Jennifer L.Warnick, Anastasia Albanese-O'Neill, et al. Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy. Journal of Pediatric Psychology, 44(1), 2019, 21–31.
6. Anderson RT, et al. 18th Congress of the International Diabetes Federation. Diabetologia. 2003;46(Suppl 2):A 275.
7. Randlov J, et al. J Diabetes Sci Technol. 2008;2(2):229-235.
8. Sherr, JL (2020, November 12-14). Impact of the MiniMed™ AHCL system on post-prandial glucose after a missed meal bolus in adolescents and adults with type 1 diabetes (T1D). 10th Annual Diabetes Technology Meeting https://journals.sagepub.com/doi/full/ 10.1177/1932296821996093.

# MiniMed™ 780G system

## with no fingersticks** in SmartGuard™ technology

The only system with meal detection technology* that provides automatic adjustments and corrections† to sugar levels every 5 minutes§




# What is meal detection technology* and how does it work?

## The system uses current and past sensor glucose (SG) trends to detect a missed meal bolus.*

If the system detects a meal based on the SGs rising rate of change, it can automatically deliver stronger correction doses† while SG values are rising, up to every five minutes.§

### Designed for real life

If carb counts are underestimated, or patient occasionally misses a meal bolus,[1] the MiniMed 780G system will automatically deliver a correction dose to get your patients back to target.

### US pivotal missed meal challenge

When participants ate a regular-sized dinner with a missed bolus, better glucose control was achieved two hours post-meal when using the MiniMed 780G system vs. the run-in phase.[8]

*Taking a bolus 15–20 minutes before a meal helps to keep blood sugar levels under control after eating.

**Fingersticks required in manual mode and to enter SmartGuard.™ If symptoms don't match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend avg of > 93% in SmartGuard.™

† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

§ Refers to SmartGuard™ feature. Individual results may vary.

1. Matejko B. et al, Diabetes Care. 2022;https://doi.org/10.2337/dc220470.

# Pivotal and real-world study results with MiniMed™ 780G system*

## US pivotal study

Time in Range results




Hybrid Close-Loop/SA2
Population that is typically well controlled, N= 157

## Real-world evidence results[9]

With recommended settings users experienced average 80.7% Time in Range


Real-world evidence all ages
Diverse population across the globe, N= 12,870


## Percentage of users achieving glycemic targets

Time in Range > 70%




Glucose Management Indicator» < 7%




**93.5%** of users achieved their glycemic targets[9] with **recommended SmartGuard settings** of 100mg/dL glucose target and 2 hours AIT (Active insulin time)

° Recommended setting users are the ones using the combination of glucose target setting at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours for at least 90% of the time. Recommended SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs.

∗ Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.

» Glucose Management Indicator (GMI) based on reported mean glucose values. Calculated using JAEB https://www.jaeb.org/gmi/.


9. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714.
10. Choudhary P. et al, Lancet Diabetes Endocrinol. 2022; https://doi.org/10.1016/ S2213- 8587(22)00245-5.
11. Medtronic data on file: MiniMed™ 780G users survey conducted in April – May 2021 in UK, Sweden, Italy, Netherlands and Belgium. N = 789.


# ADAPT study summary

Randomized controlled study evaluating the MiniMed 780G system in a population transitioning from MDI + isCGM¤ currently not meeting glycemic targets.[10]

**Early** ····· **Sustained**

Difference between groups seen as early as 3 months

Continued results through the 6-months study

**1.4%** **Lower A1C with MiniMed 780G system at 6 months**




**+27.6%** **Time in Range without hyperglycemia vs. control group**




**94%** of users are satisfied with the impact the system has on their **quality of life**[11]

"Having auto correction requires less effort from me, which allows me to participate in more things without having to experience the side effects of a high glucose. It really frees you up to focus on the other things in your life."

**– MiniMed 780G system user**

Individual results may vary. Compensated for their time. Thoughts and opinions are their own.

¤ Intermittently scanned continuous glucose monitoring (isCGM).

# Not all Automated Insulin Delivery systems (AID) are the same

## Treat to target
**MiniMed™ 780G system**

## Auto basal targets
• 100 mg/dL • 110, 120 mg/dL (optional)




## Treat to range
**T:slim X2 with Control-IQ‡**

## Ranges
• Day: 112.5-160 mg/dL • Sleep: 112.5-120 mg/dL • Exercise: 140-160 mg/dL




## Treat to target
**Omnipod® 5 with Dexcom® G6®#**

## Automated delivery targets
110-150 mg/dL in 10 mg/dL increments




‡ T:slim X2™ with Control-IQ™ + Dexcom® G6 User Guide.
# Omnipod® 5 & Dexcom® G6 User Guide.

**Fingersticks required in manual mode and to enter SmartGuard.™ If symptoms don't match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants spend average of > 93% in SmartGuard.™

# MiniMed™ 780G system components and apps

**Extended infusion set**
The only infusion set with up to 7 days of wear

**MiniMed 780G pump**
with advanced SmartGuard™ technology**

**Guardian™ 4 sensor and transmitter**
with no fingersticks in SmartGuard technology

**MiniMed mobile app**
View glucose levels, pump information, and insulin data on their phone or Apple Watch®



**CareLink™ Connect app**
shares data with up to five care partners

**My Insights email**
Provides encouragement and personalized tips based on pump and sensor data›

Smart devices sold separately.º

# Your partner in diabetes care

### Data at your fingertips
CareLink reports
- Automatic uploads of patient data«
- Provide insights that support meaningful conversations with your patients

### Provider support
HCP in-person and virtual trainings
In-person and in-office support with digital prescriptions

Medtronic Diabetes Digital University
- Flexible and convenient online training for you and your staff
- Peer-to-peer support

SCAN ME

### Personalized onboarding support
- Local and virtual training
- Patient follow-up and consistent support

### Follow-up support 24/7
- Next-day product replacements
- Continuation of therapy loaner pumps
- Online replacements for sensors and belt clips

### Patient support
- Access programs¢
- Online diabetes education
- Ambassador program
- Diabetes.shop for easy order tracking

› Requires opt-in to Personalized Insights communication preferences on Diabetes.shop/communications.
º For a list of compatible devices, visit bit.ly/CheckDevices.

¢ Terms and conditions apply.
« Internet connection required.

# MiniMed™ 780G insulin pump system

## Powered by advanced SmartGuard™ technology

**Learn more today**

Call 888-882-8602

or visit www.medtronic.com/hcp/minimed-780g

* Taking a bolus 15–20 minutes before a meal helps to keep blood sugar levels under control after eating.

**Fingersticks required in manual mode and to enter SmartGuard.™ If symptoms don't match alerts and readings, use a fingerstick. Refer to user guide. Pivotal trial participants and spend average of > 93% in SmartGuard.™

† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.

§ Refers to SmartGuard™ feature. Individual results may vary.

¤ Intermittently scanned continuous glucose monitoring (isCGM).

° Recommended setting users are the ones using the combination of glucose target settings at 100 md/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours for at lest 90% of the time. Recommended SmartGuard™ feature settings for each single patient must be defined by HCPs based on individual targets and specific needs.

› Requires opt-in to Personalized Insights communication preferences on Diabetes.shop/communications.

¢ Terms and conditions apply.

» Glucose Management Indicator (GMI) based on reported mean glucose values. Calculated using JAEB https://www,jaeb.org/gmi/.

« Internet connection required.

º For a list of compatible devise, visit bit.ly/CheckDevices.

⁎ Due to inherent analysis limitations, caution is advised.

‡ T:slim X2™ with Control-IQ™ + Dexcom G6® User Guide.

# Omnipod® 5 & Dexcom G6® User Guide.


1. Matejko B. et al, Diabetes Care. 2022;https://doi.org/10.2337/dc220470.
2. Foster NC, et al. Diabetes Technol Ther 2019 ; 21(2) :66-72.
3. Meade LT et al.. Clin Diabetes. 2016 ;34(3) : 142-147.
4. Brazeau AS, et al. Diabetes Res Clin Pract. 2013 ;99 :19-23.
5. Sarah C.Westen, Jennifer L.Warnick, Anastasia Albanese-O'Neill, et al. Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin.
6. Anderson RT, et al. 18th Congress of the International Diabetes Federation. Diabetologia. 2003:46(Suppl 2):A 275.
7. Randlov J, et al. J Diabetes Sci Technol. 2008;2(2):229-235.
8. Sherr, JL (2020, November 12-14). Impact of the MiniMed™ AHCL system on post-prandial glucose after a missed meal bolus in adolescents and adults with type 1 diabetes (T1D). 10th Annual Diabetes Technology Meeting https://journals.sagepub.com/doi/full/ 10.1177/1932296821996093.
9. Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714.
10. Choudhary P. et al, Lancet Diabetes Endocrinol. 2022; https://doi.org/10.1016/ S22138587(22)00245-5.
11. Medtronic data on file: MiniMed™ 780G users survey conducted in April – May 2021 in UK, Sweden, Italy, Netherlands and Belgium. N = 789.


**Important Safety Information: MiniMed™ 780G system with SmartGuard™ technology with Guardian™ 4 Sensor**

The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The Medtronic MiniMed™ 780G system consists of the following devices: MiniMed™ 780G insulin pump, the Guardian™ 4 transmitter, the Guardian™ 4 sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide test strips. The system requires a prescription from a healthcare professional.

The Guardian™ 4 sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ 4 sensor is indicated for up to seven days of continuous use. The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

**WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature**

**WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.**

**WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.**

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library.

**Important Safety Information: Extended Infusion Set:** The Extended Infusion Set is indicated for up to 7 days of wear for the subcutaneous infusion of insulin from an infusion pump. It is NOT indicated for intravenous (IV) infusion or the infusion of blood or blood products. Inaccurate medication delivery, infection and/or site irritation may result from improper insertion and maintenance of the infusion site. Before insertion, clean the insertion site with isopropyl alcohol. Remove the needle guard before inserting the infusion set. If using this infusion set for the first time, do the first set-up in the presence of your healthcare professional. Do not leave air in the infusion set. Prime completely. Check frequently to make sure the soft cannula remains firmly in place as you may not feel pain if it pulls out. The soft cannula must always be completely inserted to receive the full amount of medication. If the infusion site becomes inflamed, replace the set, and use a new site until the first site has healed. Replace the infusion set if the tape becomes loose, or if the soft cannula becomes fully or partially dislodged from the skin. Regularly replace the infusion set as indicated in the instructions for use, or per the insulin labeling, whichever duration is shorter. For more details, see https:// www.medtronicdiabetes.com/important-safety-information.

Accu-Chek and Accu-Chek Guide Link are trademarks of Roche Diabetes Care. For detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events, please consult the device manual. For further information, contact your local Medtronic representative.

DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed™ 780G system algorithm includes technology developed by DreaMed Diabetes.



dreamed diabetes ai

Medtronic